Leading the way to a cure

For Researchers

A complete list of Scientific Publications by Lupus Research Alliance funded researchers is available here.


Grant Application Deadline July 10, 2017

The Lupus Research Alliance invites applications for financial support for idea-driven, novel research projects relevant to basic, translational or clinical investigation in lupus.

Novel Research Grants provide early stage support for exceptionally creative and innovative approaches to major challenges in lupus research. Successful proposals will advance novel hypotheses and/or technologies that have the potential to stimulate new research directions and propel the field forward. Applications will be judged principally on novelty of the hypotheses, scientific quality, strength of approach, relevance to lupus, likelihood of success, and potential impact for those living with lupus. Rationale for the hypotheses proposed rather than amount of preliminary data will be emphasized. Continuations of long-term research projects are not appropriate for this submission.

The program goals are to stimulate investigation of underexplored pathways and initiate transformative discoveries in lupus that can drive the development of safer and more effective treatments. Investigations into the fundamental mechanisms of lupus and its complications, explorations of novel targets and pathways, and applications involving novel technologies and interdisciplinary approaches are particularly encouraged.

The Lupus Research Alliance also encourages projects based on novel explorations of lupus biology, including innovative studies that use human material to address the physiological, cellular, molecular and/or genetic basis of human lupus.

Applications from investigators in diverse disciplines, including those who may not have worked in lupus are welcomed. Both established and new investigators may apply.

Applicants should hold advanced degrees and be affiliated with institutions of higher learning. Applications from outside the United States are encouraged. Grant application research plans are limited to six pages. Annual funding of up to $100,000 per year, beginning March 2018, for a term of up to three years, will be awarded for approved projects.

Full guidelines are available here. For additional information contact Meghann Vaughn, Program Manager at mvaughn@lupusresearch.org.

To submit an Application, please visit proposalCentral at http://proposalcentral.altum.com/ and search for the Lupus Research Alliance Grant Application. Applications must be received by 5:00 PM EST on July 10, 2017.


2017 Dr. William E. Paul Distinguished Innovator Awards
in Lupus and Autoimmunity

Grant Application Deadline: May 24, 2017

The Lupus Research Alliance invites applications for its Dr. William E. Paul Distinguished Innovator Awards in Lupus and Immunology, a global program that will provide outstanding scientists with substantial support for up to four years to conduct novel research into the fundamental causes of lupus and so provide new directions toward cure or prevention.

Advances across many disciplines have led to novel treatments that aim to suppress the manifestations of lupus. Yet few interventions are being developed that seek to reverse or prevent the disease. Lupus Research Alliance Distinguished Innovators will address this gap by pioneering research into the fundamental, causative pathways of lupus.

In pursuit of this goal, the Lupus Research Alliance welcomes novel, hypothesis- or discovery-driven proposals in human and/or animal model based lupus research. The research proposal must aim to uncover the fundamental causes of lupus and present a compelling vision of how the discovery would lay the groundwork for a potential cure, prevention, or highly effective therapy.

The expert review panel will judge applications primarily on the novelty and potential of the research proposal, and the strengths and track record of the investigator. Emphasis will be on the rationale for the hypothesis rather than the amount of preliminary data. Continuations of long-term research projects will not be considered.

Successful applicants will be outstanding investigators who have demonstrated creativity and productivity in their field of research. We encourage applications from investigators in diverse disciplines including, but not limited to, immunology, genetics, molecular-, cell- and systems biology. Scientists who have not previously worked in lupus are encouraged to apply, as are researchers working outside the US. Applicants must hold a position at an academic institution.

Annual funding of up to $250,000 per year, for a term of up to four years, will be awarded for approved projects. We anticipate that no more than four Distinguished Innovator Awards will be made in 2017. The full grant application, including a research plan of no more than six pages is due by May 24, 2017.

Full guidelines are available here. For additional information contact Diomaris Gonzalez, Director, Grant Programs at research.admin@lupusresearch.org.

To submit an Application, please visit proposalCentral at http://proposalcentral.altum.com/ and search for the Lupus Research Alliance Grant Application. Applications must be received by 5:00 PM EST on May 24, 2017.

2017 Lupus Insight Prize Call for Nominations Underway

The Lupus Research Alliance is pleased to announce that the Lupus Insight Prize nominations are now underway. The Lupus Insight Prize recognizes a major, novel insight and/or discovery with the promise of changing thinking about lupus as well as a high likelihood of generating further advances in the diagnosis and treatment of the disease. Deadlines and nomination guidelines are available through the Altum proposalCENTRAL website at http://proposalcentral.altum.com/. Once there, search for the Lupus Insight Prize.

The Lupus Insight Prize recipient will be awarded $150,000 to be used for research dedicated to advancing understanding of the genetic, environmental, molecular, immunologic or cellular aspects of lupus and/or its treatment.

The full application must be submitted by the Nominator and the Candidate electronically by April 12, 2017 at 5 p.m. ET. All applications will be reviewed by members of an independent Selection Committee. Instructions on how to submit a nomination for the Lupus Insight Prize and the complete guidelines are available at here and at www.LupusInsightPrize.org.

Clinical Trials Request for Posting

Corporations, CRO’s and Investigators if you have clinical trials that you would like the ALR to post information on please click here for more information.

Below you will find links to some Clinical Trials that are looking For Researchers, Patients and to share data.

These trials are in no way affiliated with the ALR and are for informational Purposes only.

Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus

  • Atacicept is a targeted B-Cell immunomodulator which inhibits APRIL and BLyS effect as well as auto-antibody inhibition. A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE).

Embrace (Efficacy of Belimumab in Lupus Subjects of Black Race)

  • A phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52 Week Study to Evaluate the Efficacy and Safety of Belimumab in Adult Subjects of Black Race with Systemic Lupus Erythematosus.

Bliss- SC Belimumab International SLE Study – Subcutaneous

  • A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously to Subjects with Systemic Lupus Erythematosis (SLE).

Belimumab (Benlysta) Pregnancy Registry - Prospective Cohort Study of Pregnancy Outcomes following Belimumab Exposure

  • The Belimumab Pregnancy Registry is a global, observational cohort study. It will collect prospective pregnancy outcome data on a voluntary basis in women with systemic lupus erythematosus (SLE) who have received belimumab (Benlysta). Infant outcomes from babies born to mothers in this Registry will also be evaluated. Registry data will add to the current clinical experience with belimumab and complement reproductive data from animal toxicology studies. This Registry is sponsored by GlaxoSmithKline (GSK) and managed by Pharmaceutical Product Development (PPD), Inc

Bliss – LN Belimumab International Lupus Nephritis Study

  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care Induction and Maintenance Therapy for Active Lupus Nephritis.

PLUTO – (Pediatric Lupus Trial Of belimumab)

  • A Multi-Center, Randomized Parallel Group, Placebo-Controlled Double-Blind trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, A Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Patients with SLE.

SABLE SLE Registry

  • A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults with Active, Autoantibody-Positive SLE Treated with or without BENLYSTA (belimumab) (SABLE).

BASE (Belimumab Assessment of Safety in SLE)

  • A Randomized, Double-Blind, Placebo-Controlled 52 Week Study to Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab.


Last Name

First Name








Hospital for Special Surgery




Gerald T.

M.D. / Ph.D

Immune Tolerance Network, National Institutes of Health
Benaroya Research Institute at Virginia Mason










Anthony J.


Centers for Therapeutic Innovation, Pfizer Inc.






Stanford University






University of California, San Diego






BL Kotzin, Inc.






Baylor Institute for Immunology Research



David S.

M.D. / Ph.D

Duke University Medical Center






Hospital for Special Surgery




Benjamin D.

M.D. / Ph.D

The Camden Group; Washington University School of Medicine




Mark J.

M.D. / Ph.D

University of Pittsburgh






Beth Israel Deaconess Medical Center



2017 Lupus Research Alliance Scientific Calendar

View Our special reports on the ACR and other Meetings

  January 25, 2016 Target Identification Grant Applications Due  
  June 2016 Scientific Advisory Board Meeting  
  April 1, 2016 IFNB ALR/CTI Challenge Grant Applications Due  
  April 29, 2016 Lupus Insight Prize Nominations Due  
  June 23, 2016 Lupus Insight Prize Ceremony  
  October 24 - 25, 2016 Annual Collaborative Scientific Conference  

Scientific Meetings

January 28 - 31, 2017 The 56th Midwest Conference of Immunoligists at Asilomar - Frequency - Every Year
March 2 - 4, 2017 European Workshop for Rheumatology Research - Frequency - Every Year
March 9 - 11, 2017 The Third International Congress on Controversies in Rheumatology & Autoimmunity - Frequency - Every Two Years
March 26 - 29, 2017 The 12th International Congress on Systemic Lupus Erythematous (LUPUS 2017) & the 7th Asian Congress on Autoimmunity (ACA 2017) Melbourne, Australia - Frequency - Every Two Years
May 5 - 7, 2017 6th Annual Meeting of the Lupus Academy: Programme The Portugal - Frequency - Every Year
May 12 - 16, 2017 The American Association of Immunologists - IMMUNOLOGY 2017 - Washington D.C. - Frequency - Every Year
June 14 - 17, 2017 EULAR Congress 2017 - Madrid - Frequency - Every Year
June 14 - 17, 2017 Federation of Clinical Immunology Societies 20174 - Chicago - Frequency - Every Year
June 29 - July 01, 2017 8th European Immunology Conference, Madrid, Spain - Frequency - Every Year
July 1 - 4, 2017 10th Frontiers in Immunology Research International Conference - Island of Crete Greece - Frequency - Every Year
October 16 - 20, 2017 19th Asia Pacific League of Associations for Rheumatology Congress - Dubai World Trade Center U.A.E. - Frequency - Every Year
November 3 - 8, 2017 ACR / ARHP Annual Meeting - Frequency - Every Year
November 17 - 20, 2017 Autumn Immunology Conference (AIC) 2017 - Frequency - Every Year

Special Reports

View Highlights from the ALR's 2013 American College of Rheumatology Annual Scientific Meeting

View highlights from the ALR's 2011 American College of Rheumatology Annual Scientific Meeting

View highlights from the ALR's 2010 American College of Rheumatology Annual Scientific Meeting

View the Lupus Congress 2010 Special Report

1.5 million

people in the U.S. have Lupus.

172 million

dollars committed to lupus research by the Lupus Research Alliance.

We're walking across the United States to raise awareness and funds for lupus research.


Show your support by visiting the Lupus Research Alliance online store. Discover the perfect gift, or prepare for a walk with our selection of apparel and accessories.

Powered by Blackbaud
nonprofit software